Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
- · 40d
- Not stated
- Not stated
- Nov 22, 2024
Official announcement on nih_guide+grants_gov · opens the funder's page. Always confirm dates there.
Summary
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and… […]
Other topics in this solicitation
Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
$350k
Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
The rest of this announcement — free with an account
- The full announcement text, not the first two sentences
- All 4 review criteria reviewers score this against, extracted from this announcement
- Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- What similar funded projects received, from 219,000 past awards
More from National Institutes of Health
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
$250k
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
$350k